InsidersTradesSigma
Follow the BETA BIONICS INC share price and the full directors' dealings record of the company, a listed equity based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Market capitalisation: €887.2m. The latest transaction was filed on 3 September 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Sean Saint. All data is free.
Analysts rate BETA BIONICS INC Buy (bullish), based on 11 analysts. Average price target: US$20.31.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
2 of 2 declarations
BETA BIONICS INC 是一家专注于开发糖尿病管理医疗设备的公司。它旨在利用技术创新提高患者的生活质量。